How Medical Devices Get Reimbursed: The Medicare Coverage Pathway Explained

Device reimbursement in the United States runs through Medicare's coverage machinery: an item must fall within a statutory benefit category and be reasonable and necessary for diagnosis or treatment before payment follows. National coverage determinations are made through an evidence-based process with public participation, per the Centers for Medicare and Medicaid Services — separate from FDA clearance.

Why is FDA clearance not enough to get paid?

Regulatory clearance answers whether a device is safe and effective for its intended use. Coverage answers a different question: whether a payer will pay for it in a defined population. A device can hold 510(k) clearance and still lack any coverage pathway, because CMS evaluates whether the evidence supports the item being reasonable and necessary for the Medicare population — typically meaning evidence in the population, indication and setting of expected use, not merely in registry-enriched cohorts or younger patients.

The second gate is the benefit category. Requests must identify the benefit category the requester believes matches the item. Certain items are statutorily excluded regardless of evidence — CMS's guidance cites hearing aids, certain dental services and cosmetic surgery — so a technically successful device outside any category has no coverage path without legislation.

What is the difference between an NCD and an LCD?

Per CMS's coverage determination process page, in the absence of a national coverage policy, an item or service may be covered at the discretion of Medicare administrative contractors based on a local coverage determination, which applies only within that contractor's jurisdiction. An NCD, by contrast, binds the program nationally. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 amended several portions of the NCD development process with an effective date of January 1, 2004, and CMS's current process follows the Federal Register notice of August 7, 2013 (78 FR 48164).

How does the NCD process run step by step?

A complete, formal request can be initiated either by an outside party or internally by CMS staff, and requests are accepted on a rolling basis, prioritized by the magnitude of potential impact on the program and its beneficiaries and by staffing resources, per the agency's process and timeline guide:

1. A requester submits a complete formal request, including the benefit category, supporting evidence and documentation, information on usefulness and benefit to the Medicare population, and a complete explanation of the design, purpose and method of using the item.
2. CMS accepts or declines the request and opens a national coverage analysis if accepted.
3. CMS gathers evidence, at times commissioning an outside technology assessment and consulting the Medicare Evidence Development and Coverage Advisory Committee.
4. CMS publishes a proposed decision for public comment.
5. CMS finalizes the determination, and the policy takes effect on a stated date.

What role does evidence development play?

Where evidence is promising but incomplete, CMS can link coverage to additional data collection — coverage with evidence development — so that payment proceeds alongside registries or studies that answer the open questions. For investigational devices, coverage is also tied to the framework for IDE studies. These routes recognize that device evidence matures after market entry, but they add design obligations that companies must plan for years ahead of a launch.

What should a device company do with this map?

Treat reimbursement as a second development program running in parallel with regulatory work. That means generating coverage-grade evidence — relevant populations, clinically meaningful endpoints, adequate follow-up — and choosing deliberately between a national determination, which suits technologies with broad expected use, and contractor-by-contractor coverage, which can be faster but produces a patchwork. The formal request itself is a regulatory document: incomplete requests are declined on completeness grounds before science is ever discussed.

How do old policies get revisited?

The coverage landscape also ages in place. CMS's process notice of August 7, 2013 outlined an expedited administrative process, using specific criteria, to remove certain NCDs older than ten years since their most recent review — freeing Medicare administrative contractors to determine coverage locally under the Act. The effect is a deliberate devolution: national policies that no longer reflect current evidence can be retired to local discretion rather than rewritten centrally, which creates both opportunity and inconsistency for device companies whose products were covered — or restricted — under an aging national policy.

For a device manufacturer, that mechanism is a strategic lever. A technology restricted by a national policy written a decade or more ago, in an era of thinner evidence, may find that the fastest route to broader coverage runs through reconsideration or through the retirement of the old determination rather than through a fresh evidence program. Reading the date on the governing NCD is therefore as important as reading its text.

What are the common failure modes for device companies?

Four recur. Companies pursue regulatory clearance with populations and endpoints chosen for the agency, then discover that the Medicare population — older, more comorbid, treated in different settings — was never studied, leaving the coverage file thin where it matters. Companies assume that a CPT code implies payment at a workable amount, when coding, payment rates and coverage are separate decisions. Companies underestimate the completeness bar for a formal NCD request and lose months to a declined filing. And companies plan launches around clearance dates with no reimbursement calendar at all, so the device reaches the market and stalls in procurement while the coverage process runs.

Each failure mode has the same root: treating reimbursement as a commercial afterthought rather than a parallel regulatory pathway with its own evidence standard, its own decision documents and its own calendar. The device companies that scale reliably are the ones that write the coverage plan before the pivotal trial is designed — because the trial that satisfies the agency and the trial that satisfies the payer are not always the same trial.

What happens after coverage is secured?

Coverage is the first of three gates, not the last. Coding determines whether a claims pathway exists for the service; payment rules determine what the item or service actually earns; and contractor discretion within local coverage determines how consistently claims are paid in practice. A device with national coverage but no straightforward coding can spend its first commercial year in manual claims review, and a device with coding but restrictive local policies can see materially different utilization across contractor jurisdictions for the same technology.

This is why reimbursement planning documents usually track a pathway matrix: for each target setting and payer, the benefit category, the governing coverage policy — national or local — the codes to be used, and the expected payment. Building the matrix early exposes the gaps while they can still be fixed with evidence, rather than after launch when they can only be fixed with lobbying and time.

How does the public participate?

Both coverage tracks are formally open to participation, and the mechanism differs by level. National coverage analyses run through published proposed decisions with comment periods, and the MEDCAC advisory committee meetings are public, with agendas, presentations and voting questions posted in advance. Local coverage determinations carry their own contractor comment processes. Manufacturers, clinical societies and patient organizations all file comments in meaningful numbers on consequential decisions — which is why the readable record of a technology's coverage fight is usually longer than its clinical literature.